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Over the last 5 years, genome engineering has emerged as one 
of the most powerful molecular tools with potential therapeutic 
applications. Though traditional gene therapy has come a long way, 
as evidenced by the recent licensing of Strimvelis as a gene therapy for 
severe combined immunodeficiency (SCID), nonspecific insertional 
oncogenesis remains a concern.[1] Genome engineering technology 
bypasses this issue through targeted disruption of the genome – 
acting as GPS coordinates for the intended genetic modification 
at a specifically designated site. With the recent advance and ease 
of use of the clustered regularly interspaced short palindromic 
repeats (CRISPR) technology, gene editing has been catapulted to 
the forefront of molecular and cellular biology, and the public eye.[2] 
In this review, we will highlight the general approaches to targeting 
disease by expanding on a few of the most successful studies to date, 
though this is in no way an exhaustive review of all diseases amenable 
to genome engineering therapies. Using these established methods, 
we then discuss potential approaches that could have an impact on 
South African health burdens, taking into account the unique genetic 
diversity of the diaspora. 
Principles of genome engineering
The basic approach for genome engineering involves the use of 
specialised ‘molecular scissors’ called endonucleases which can be 
designed to target a specific sequence of genomic DNA (gDNA) and 
induce a double-strand break (DSB). The most frequently exploited 
of these are zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs) and CRISPR.[3] DSBs stimulate the cell’s 
repair machinery, either using the non-homologous end joining 
(NHEJ) or homology-directed repair (HDR) processes (Fig. 1). NHEJ 
often leads to incorrect insertions or deletions (indels) in the DNA. In 
a coding region of the genome this can be exploited to permanently 
knock out a gene as a result of a shift in the reading frame, creating 
a non-functional protein, and thus, gene ablation. This offers an 
opportunity to deactivate the deleterious gene in disorders with 
gain-of-function mutations. Though relatively efficient, this does not 
allow for accurate repair of loss-of-function mutations. Fortunately, 
exploitation of the HDR pathway during cell division with the 
addition of a synthetic DNA template can lead to gene correction. 
The efficiency of this process is significantly lower than NHEJ, and it 
is therefore critical that design strategies take this into consideration. 
The development of an endonuclease-deficient variant of CRISPR-
associated protein 9 (Cas9), dead Cas9 (dCas9), has allowed us to go 
beyond these classic genome engineering strategies which rely on the 
introduction of a DSB. By fusing dCas9 to transcriptional repressors 
(CRISRPi)[4] or activators (CRISPRa),[5] loss- and gain-of-function 
studies can be carried out independently of a DSB.
Despite the specificity of targeting, some off-target DSBs can occur, 
especially when using CRISPR. ZFNs and TALENs are considered to 
lead to fewer off-target effects across the genome. In addition, TALENs 
have unlimited targeting sequence ability, while CRISPR requires a 
recognition sequence of ‘NGG’ to exert its effect.[6] However the design 
of these endonucleases is substantially more technically challenging, 
and therefore they are adopted less frequently than CRISPR.
Therapeutic approaches
There exists a myriad of ways in which genome engineering can 
be exploited for therapeutic uses (Fig. 2). Importantly, these reflect 
similar strategies used in traditional gene therapy research, but will 
be expanded upon here by showcasing some of the most recent and 
impactful research.
In vivo therapeutic engineering makes use of well-established 
viral vector delivery, in which the endonuclease and, if necessary, 
the repair construct, are integrated into recombinant viruses such 
as adeno-associated viruses (AAVs) and lentiviral vectors.[7] These 
vectors can be manipulated to restrict tropism to a specific cell type, 
to enhance the specificity of the endonuclease to disease-specific 
cellular damage. Delivery can be systemic or localised to the area 
where it is most required, e.g. intrastriatal or intramuscular to 
increase the proportion of genetically corrected cells necessary for 
measurable clinical improvement (Fig. 2A). 
A recent study by Amoasii et al.[8] used such a strategy to 
repair a mutation in the dystrophin gene in a canine model of 
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Duchenne muscular dystrophy (DMD). 
Many dystrophin mutations cause a 
frameshift of the coding region, and thus a 
truncated, non-functional protein leading 
to cardiomyopathy-induced lethality. 
Directly skipping exon 51 by targeting a 
splice-acceptor site would repair the reading 
frame, thereby partially restoring dystrophin 
function in 13% of DMD patients. This offers 
an ‘off-the-shelf ’ treatment for a significant 
proportion of individuals.[9] Post-mitotic cells, 
such as skeletal and cardiac muscle, undergo 
very low levels of HDR. The exploitation 
of NHEJ repair in terminally differentiated 
cells can, however, allow for skipping of a 
deleterious exon following DNA break 
induction. Despite the preliminary nature of 
the study, this is one of the most promising 
in a large animal model, demonstrating 
restoration of dystrophin production in all 
muscles after systemic injection of 1 × 1014 
AAVs9 viral particles containing CRISPR-
Cas9 components. Importantly, the authors 
showed a lack of immune reaction through 
undetectable CD4 infiltration. Critically, both 
the diaphragm and cardiac muscles showed 
over 50% improvement in protein levels. 
This successful example of in vivo genome 
engineering brings to the fore another crucial 
aspect in that the proportion of repaired 
cells needed to elicit meaningful phenotypic 
benefits is disease-specific. In DMD, it has 
been shown that only 15% homogenous 
expression may be sufficient to slow down 
disease significantly in a mouse model.[10]
Another strategy of therapeutic genome 
engineering includes an ex vivo approach, 
whereby cells from an individual can be 
extracted, corrected in a dish, and then 
replaced (Fig. 2B). This offers advantages 
over in vivo treatments, as only corrected 
cells could be selected, enhancing the 
impact of mutation correction. This 
is best exemplified by FDA-approved 
immunotherapy treatments targeting 
CD19 antigens on cancer cells engineering 
chimeric antigen receptors on T cells 
(CART). In 2015, a 6-month-old patient was 
diagnosed with acute lymphoid leukaemia 
(ALL) with conventional treatments having 
failed. Using previously established CART 
cells, the team used TALENs to disable the 
T cell receptor alpha (TCRɑ) gene to prevent 
these cells from causing graft-versus-host 
disease upon infusion.[11] Three years 
later, the patient has been reported to be 
in remission. Subsequently, CART therapy 
has rapidly evolved to include other blood 
cancers, including Kymriah (Novartis, 
Switzerland) for all and non-Hodgkin 
lymphoma, and Yescarta  (Kite Pharma, 
USA) for diffuse large B cell lymphoma.[12] 
In addition, research is now expanding 
these successes towards targeting solid-state 
tumours.[13] However, ex vivo treatment 
incurs additional issues in that, while it 
is desirable for infused cells to proliferate 
and mount a strong attack on cancer cells, 
they can create cytokine release syndrome, 
which is essentially a cytokine storm 
leading to life-threatening side-effects.[14] 
As a result, Cellectis has genetically 
engineered a safety switch in CART cells, 
yielding the foreign cells susceptible to 
rituximab, the FDA-approved antibody 
enabling control of infused cells should 
life-threatening side-effects emerge.[15] 
These and other improvements could 
propel CART therapy into mainstream 
treatment options; however, the cost 
(approaching USD500  000) per treatment 
remains a significant challenge. Off-the-
shelf allogeneic treatments through the 
promotion of public cell banks, with 
standardised manufacturing pipelines, 
could go a long way towards a more cost-
effective approach.[16] 
However, adult stem cells do not provide 
the means to make all cell types. For many 
neurodegenerative disorders, for example, 
mature neurons are needed to replace 
damaged cells. Pluripotent stem cells 
(PSCs), both embryonic stem cells (ESCs)[17] 
and induced pluripotent stem cells 
(iPSCs),[18] offer a unique opportunity to 
address this challenge. On the escarpment 
of Waddington’s landscape, they provide 
a source of cellular material able to 
generate any cell type in the body, including 
a fimultitude of neuronal cell types.[19] 
Importantly, iPSCs can be generated in a 
patient-specific manner (Fig. 2B), which 
negates the need for harmful immune 
suppressors, while incorporating gene 
corrections. Several studies led by the 
Gforce-PD consortium have made advances 
in cell-replacement therapies.[20] In October 
2018, Jun Takahashi and his team at Kyoto 
University coaxed healthy, allogeneic 
iPSCs into neuronal cells (precursors to 
dopaminergic neurons) in vitro, which were 
subsequently implanted into the brain of 
a 50-year-old Parkinson’s patient.[21] It is 
important to note that allogeneic matching 
of healthy iPSCs may bypass the need for 
gene correction entirely. 
Isogenic PSCs further provide a method 
for indirect therapeutic applications. 
Here, genome engineering can be used to 
include specific mutations in separate cell 
lines, providing a phenomenally accurate 
screening tool (Fig. 2C). Researchers can 
use these disease-in-a-dish models to 
investigate the contributions of specific 
mutations to the disease without the 
significant background genetic variation, 
which can confound in vitro phenotypes.[22] 
Similar genome engineering screening 
models can reveal novel targets in T cell 
immunotherapy. Patel et al.[23] performed 
a CRISPR screen in T cells, and observed 
the effectiveness of individually mutated T 
cell clones in targeting melanoma cells in 
vitro. While these may not fall under the 
umbrella of cellular replacement therapy, as 
a tool, they provide an indirect therapeutic 
strategy by identifying novel pathways that 
Fig. 1. Genome-editing repair mechanisms. Targeted double-strand break (DSB) results in the cellular 
machinery rapidly repairing the break via the error-prone non-homologous end-joining (NHEJ) error-
prone pathway, which often results in insertions and deletions (indel). During mitosis, an alternative 
repair pathway can be employed, in the presence of a repair template (homology-directed repair (HDR)) 
to create a precise gene edit at the site of the DSB. 
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can be targeted to improve immunotherapy 
outcomes. 
Genome engineering for 
South Africa
South Africa (SA) is crippled with a high 
burden of infectious disease, and increasing 
incidences of non-communicable diseases. 
One may argue that we should channel 
our limited resources into tackling these 
health issues first, and allow the West to 
research advanced genome engineering 
technologies that could apply to our 
patients once developed. However, a ‘one-
size-fits-all’ therapeutic approach is often 
not feasible because of the unique genetics 
and admixture of our population groups. 
Here, we evaluate the potential for genome 
engineering strategies to tackle diseases 
that would impact on social, genetic and 
economic issues pertinent or unique to the 
country. 
Infectious disease
In 2017, SA’s HIV expenditure was over 
USD2 billion.[24] Notably, these life-saving 
treatments have also been associated with 
a number of adverse side-effects that are 
significantly more prevalent in individuals of 
African descent.[25] Thus, while current ART 
approaches continue to play an essential role 
in curbing AIDS-related mortalities there is a 
clear need for therapeutic cures.
Gene therapy-based approaches have 
long represented promising avenues of 
research given the characterisation of rare 
human genetic variants that confer natural 
resistance against HIV.[26] The most well 
characterised of these is a 32 base pair 
deletion in the gene encoding the chemokine 
receptor, C-C chemokine receptor type 
5 (CCR5). This mutation, referred to as 
CCR5-∆32, is most common in individuals 
of Northern and Eastern European descent 
(~10%), where a homozygous deletion of 
CCR5 results in complete viraemic control 
and heterozygosity results in delayed disease 
progression to AIDS. The landmark Berlin 
patient publication of 2009 demonstrated 
how an HIV-positive patient with leukaemia 
was cured of HIV through a haematopoietic 
stem-cell (HSC) transplant from an HLA-
matched, CCR5-∆32 homozygous donor.[27]
Allogeneic matching of donors may not 
be feasible in the highly diverse genetic 
populations in SA. The use of genome-
editing strategies to first engineer and later 
reintroduce autologous cell populations may, 
however, overcome many of the challenges 
associated with donor-transplant approaches.
Numerous studies have demonstrated 
promising results for genome-engineering 
strategies in the fight against HIV/AIDS 
through the ablation of HIV-associated 
co-receptors (CCR5 and C-X-C chemokine 
receptor type 4 (CXCR4))[28] and the viral 
regulatory proteins from infected T cell 
populations.[29] Other studies have created 
second generation CART therapy to 
develop HIV-resistant T cell populations[30] 
or deleted HIV promoter elements from 
circulating cells in patient-engrafted mice.[31] 
Finally, using derivations of the CRISPR 
system, eradication of latent viral reservoirs 
through CRISPR-based activator systems 
has been achieved using in vitro T cell 
models of latency where a >85% activation 
rate was observed.[32] HIV further lends 
itself to genome engineering knockout 
screens and the subsequent identification 
of novel drug targets as suggested in Fig. 
1C.[33] At the CSIR, we have utilised CRISPR-
based technology to produce iPSC-derived 
macrophages, incorporating biallelic CCR5 
gene ablation as well as African relevant 
3D hepatic models, for the evaluation of 
ART-associated adverse drug reactions 
(unpublished data). These examples of in 
vivo therapeutic genome engineering and 
indirect in vitro studies may significantly 
impact the crippling cost of life-long 
antiretroviral therapy. 
Hepatitis B virus (HBV) has reliable 
prophylactic vaccines but no permanent 
cure. With inadequate vaccine deployment, 
chronic HBV infection leads to cirrhosis and 
hepatocarcinoma. HBV undergoes several 
stages of its life cycle but is susceptible at 
one particular point. Targeting of the 
stable episomal covalently closed circular 
DNA (cccDNA) of the virus provides an 
opportunity to permanently disable the 
virus, since it encodes a number of essential 
regions, rendering it susceptible to genetically 
engineered disruptions.[34] Research into 
targeting HBV is being led by Arbuthnot et 
al.[35] at the University of the Witwatersrand, 
demonstrating one of the first uses of 
targeting the virus directly using TALENS. In 
essence, this would provide a mechanism for 
inhibiting the re-emergence of latent viruses. 
Effective approaches targeting the cccDNA of 
HBV are still reliant on efficient delivery of 
genome-engineering tools to hepatocytes.[36]
Many viral vectors, like AAVs, can only 
deliver small genomic cargo. Advances made 
in derivations of CRISPR-Cas9, for example 
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Fig. 2. An overview of the CRISPR/Cas9 therapeutic approaches. (A) In vivo therapies package the 
CRISPR/Cas9 genome engineering components into viral vectors which are injected systemically or site-
specifically into a patient. The viral vectors are tuned to infect specific cell types and deliver the CRISPR/
Cas9 payload for corrective genome engineering. (B) Ex vivo approaches involve removing the patient 
cells and genetically manipulating them in a tissue culture dish. This can be done directly in adult cells, 
or in reprogrammed iPSCs, which subsequently have to be differentiated into the cell type of interest. 
The corrected cells are selected for, expanded and then reinfused into the patient as an autologous 
transplantation. (C) Genome-wide CRISPR/Cas9 knockout screens can be used to elucidate novel drug 
targets by assessing drug efficacy in the context of de novo CRISPR/Cas9-induced gene mutations. 
(CRISPR = clustered regularly interspaced short palindromic repeats; iPSCs = induced pluripotent stem 
cells; Cas9 = CRISPR-associated protein 9.)
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using the smaller saCas9, will thus significantly aid curative treatments 
for HBV.[37]  
Albinism
Albinism has a special significance in SA due in part to the 
climate, social discrimination and abuse experienced by patients,[38] 
notwithstanding the clinical phenotype, which includes increased 
susceptibility to cancer and poor eyesight.[39] In one form, as a result 
of a founder mutation in Africans, a mutation in the oculocutaneous 
albinism 2 (OCA2) gene leads to an incidence of 1/3 900 SA 
individuals. It is therefore the most common recessive disorder in 
SA, with 80% of patients carrying a 2.7 kb deletion in exon 7.[40] 
The deletion leads to reduced production of a protein essential 
to melanin production. Given the complexity of skin structure, 
an ex vivo therapeutic approach involving gene correction, and 
subsequent transplantation of healthy melanocytes, is not currently 
feasible. However, genome engineering of isogenic iPSCs, could 
remove compounding genetic variation between individuals to 
exclusively compare cells with and without the mutation. Subsequent 
differentiation into melanocytes and retinal pigment epithelium 
(RPE) would then provide a screening tool with which to identify 
drugs that may alleviate melanin production, as is being researched 
for OCA1.[41] Thus, an indirect therapeutic approach specifically 
for OCA2 SA patients would significantly impact the lives of these 
patients. 
Neurodegenerative disorders
Disorders that lead to degeneration of neurons fall short of treatment 
options globally. While genetic research has led to discoveries 
of how mutations cause disease, diagnosis has largely been the 
only contribution towards managing symptoms without significant 
treatment options. Spinal muscular atrophy (SMA) is an autosomal 
recessive disease frequently caused by a homozygous deletion of 
the SMN1 gene. However, an evolutionary backup in the form of a 
duplication, results in the presence of the SMN2 gene that can, with 
increased expression, rescue the degeneration of motor neurons.[42]
A single nucleotide mutation in the SMN2 gene prevents correct 
splicing and thus expression of SMN protein from this backup gene. 
Targeting this small genetic change is a recently approved FDA and 
EMA treatment, which uses intrathecal delivery of an antisense 
oligonucleotide (Nusinersen), and displaces the splicing machinery, 
producing fully functional SMN protein.[43] However, as the treatment 
effects are transient, repetitive injections may be required to avoid 
the detrimental developmental effects of the mutation. Thus, a 
permanent ‘once-off ’ genome-engineering strategy would benefit 
these patients. However, CRISPR-Cas9 cannot always target specific 
mutations due to the requirement of a specific NGG recognition 
sequence. Using a modified version of CRISPR (CRISPR-Cpf1), 
Zhou et al.[45] were able to identify suitable endonucleases that would 
allow repair of this mutation, leading to restoration of SMN protein 
in patient-specific iPSCs.However, it is estimated that only 50% of 
patients in SA have the homozygous deletion mutation exhibited 
globally, due to the complexities of the genomic rearrangements 
of the region.[46] Furthermore, they reveal frequent deletions of 
SMN2,[47] suggesting targeting of SMN2 to restore SMN protein will 
have limited impact in SA patients. Therefore, if iPSC technology 
using SA SMA patient-specific cells could be generated, rescue of the 
mutation could reveal whether these unique patients would benefit 
from genome engineering targeting the SMN2 gene rearrangement. 
Spinocerebellar ataxia type 7 (SCA7) offers another opportunity to 
address an African-specific neurodegenerative issue using allele-
specific gene ablation, as it is more common in SA than anywhere else 
in the world.[48] SCA7 is an autosomal dominant disorder caused by 
an expansion of a trinucleotide repeat producing aggregates of toxic 
protein in cerebellar glia and the degeneration of Purkinje neurons. 
With no treatment options, this results in a multitude of defects 
and lethality within a few years. While gene therapy strategies have 
been researched with the view to reducing expression of the mutant 
protein, they are, as with the SMA approach, transient. However, 
targeting the mutation (an expansion of >40 CAG nucleotide repeats) 
would be inadvisable owing to the number of similar sequences the 
endonuclease would inadvertently damage in the genome and the 
normal allele. Since retaining the one correct version of the allele 
is known to be necessary for normal development, removing just 
the mutated gene is preferable. Due to a founder effect in black SA 
patients, a single-nucleotide variant has been found to track with 
the mutant allele.[49] Thus, using allele-specific genome engineering, 
targeting of this single nucleotide variant could be used as a unique 
strategy to destroy the mutated allele in 50% of SA patients. A similar 
strategy with in vivo viral vector transduction was deemed feasible for 
Huntington’s disease, another polyglutamine disease.[50] 
Conclusion
We chose to showcase diseases where a significant South African 
component exists, highlighting a few with genetic, societal and/
or environmental impact. There are many other diseases for which 
genome engineering could be applied in the unique SA context, e.g. 
cystic fibrosis, beta-thalassaemia and Fanconi anaemia, to name a 
few.[46] The challenges are significant, not least of which is the cost 
of such treatments. We must also acknowledge the health burden in 
SA. Drug-resistant pathogens are considered one of the WHO’s most 
serious health concerns. This, in addition to a lifetime of adverse 
drug reactions to ARVs, may promote an open-minded attitude 
towards researching previously considered ‘science-fiction’ genome-
engineering treatments. Furthermore, many of the diseases discussed 
here have no current treatments, and so, compassionate therapies 
like the one described for the 6-month-old ALL patient, should be 
investigated. 
In addition, the scientific community must be prudent in addressing 
ethical concerns related to genome engineering (succinctly discussed 
here).[51] This is especially important because of recent events in 
China, where genetically engineered twin girls were born (to an HIV-
positive father) with modifications to their CCR5 genes in an attempt 
to create immunity to HIV. The litany of issues that were raised 
launched an international outcry; it was unnecessary (sperm-washing 
can eliminate the virus prior to IVF), incomplete (one of the girls was 
only heterozygous and therefore not protected from HIV), performed 
without ethical approval, and has potentially led to their increased 
susceptibility to other infectious diseases and impairment of neuronal 
development.[52] The argument for pioneering germline editing lies in 
advancing the ability to correct many inherited mutations. However, 
whether germline editing is ready for the clinic is a moot point. The 
well-established technology of pre-implantation genetic diagnosis 
already provides a non-invasive method of excluding inheritance of 
harmful genetic mutations. Therefore, regulatory authorities must 
develop watertight rules governing the use of genome engineering. 
Nonetheless, our country’s unique health issues and related genetic 
diversity necessitate unique solutions. With well-informed debate 
and scientific oversight, genome engineering could hold the potential 
to unlocking these solutions. 
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